Enclomiphene · trans-Clomiphenenot a peptide — a small-molecule SERM that raises your own testosterone, with real data but no approval

Real endocrine data — rejected twice, banned in sport.

Enclomiphene is, like tesofensine, an investigational small-molecule oral drug rather than a nutrient or peptide — specifically a SERM, the trans-isomer of clomiphene. Its honest picture is genuinely favorable on mechanism and short-term endocrine data: across multiple randomized human trials and a 2025 meta-analysis, it reliably raises total testosterone, LH, and FSH in men with secondary hypogonadism, and — unlike testosterone gel, which suppresses gonadotropins and can impair sperm production — it preserves the fertility axis. That earns a real Grade B (the meta-analysis A/B). But three things keep it firmly investigational: it is not FDA-approved (Androxal got a Complete Response Letter in 2015) and was refused by the EMA (EnCyzix, 2018); it carries SERM-class risks (visual symptoms that can persist, thromboembolic concern, mood effects, estradiol shifts); and it is prohibited in sport (WADA S4). The page separates the solid endocrine-effect evidence from the regulatory rejection and the long-term-outcome uncertainty.

Trick the brain into making more of your own testosterone.

Enclomiphene's mechanism is clean and well-supported by human endocrine data. Normally, estrogen (made partly from testosterone) signals the hypothalamus and pituitary to dial back reproductive hormones — a negative feedback loop. As a SERM, enclomiphene blocks estrogen receptors at those feedback nodes, so the brain "sees" less estrogen and ramps up GnRH, driving the pituitary to release more LH and FSH. LH tells the testes' Leydig cells to make testosterone; FSH supports the Sertoli cells that drive sperm production. The crucial contrast with testosterone replacement: TRT adds hormone from outside and *suppresses* LH/FSH (shrinking the fertility signal), while enclomiphene *raises* them — which is why it's framed as fertility-preserving. The mechanism is Grade B (established in controlled male studies); the estradiol rise and the isomer-specific behavior are real but with practice-pattern, not validated, monitoring thresholds.

An oral tablet, not a reconstituted peptide.

Critical for this page: enclomiphene is a small-molecule oral tablet, not a peptide and not reconstituted — so there is no BAC water, no syringe units, no draw-volume math. Dosing is simply tablets/capsules per day in milligrams. There's also no FDA-approved standalone label; everything below is research architecture derived from human study doses, not prescribing instructions. Human dose-ranging studies used oral 6.25, 12.5, and 25 mg once daily, with practice often centering on 12.5–25 mg/day. The half-life is roughly 10 hours (approximate — no approved-label PK exists), so this is a once-daily oral compound; the calculator below is an oral dose planner / tablet-splitting tool, not a dosing recommendation.

One sensible pairing — and a self-defeating one.

Enclomiphene's combination logic is governed by the same endocrine feedback it exploits. The one pairing that fits the mechanism is monitoring rather than a drug: combining enclomiphene with regular semen analysis when fertility preservation is the actual reason for choosing it over TRT. Beyond that, the picture is mostly cautionary. Combining it with hCG (an LH-receptor agonist) stacks two different stimulation nodes and can push testosterone and estradiol high; pairing it with an aromatase inhibitor is a common practice-pattern move if estradiol rises, but over-suppressing estrogen harms libido, mood, bone, and lipids. And the self-defeating combination is enclomiphene plus TRT: since exogenous testosterone suppresses LH/FSH, adding it directly undoes the fertility-preserving rationale that makes enclomiphene attractive in the first place. The throughline: every "stack" here distorts the LH/FSH/testosterone/estradiol picture and needs clinician oversight, not casual layering.

A SERM's risks — vision, clots, mood, and an unproven long game.

Enclomiphene's safety profile is the SERM-class profile, characterized through its own development dossier and the well-established clomiphene label. The most distinctive concern is visual: the clomiphene class warns that blurring, spots, or flashes can occur and sometimes persist after stopping — a genuine hard-stop signal. The EMA's EnCyzix assessment flagged headache, hot flushes, nausea, muscle spasms, blurred vision, and — importantly — venous thromboembolic and cardiac-disorder concerns, which is part of why it was refused. Mood changes (irritability, aggression) appear in safety discussions and comparative work, and because the drug raises testosterone, estradiol can rise as a downstream consequence. Two honest framings matter: the fertility-preservation benefit is real on average but not guaranteed for an individual (it must be measured), and the long-term safety and clinical-outcome data simply aren't mature. This is a prescription-grade endocrine drug requiring baseline screening and ongoing monitoring, not a self-managed compound.

Practical safety framework

Contraindications & cautions

Consistent endocrine data, capped by no approval.

Enclomiphene's evidence base is, like tesofensine's, unusually solid for an unapproved compound — and concentrated on its endocrine effect. Across multiple randomized phase-II-style trials (Wiehle 2013/2014, Kaminetsky 2013, Kim 2016) and a 2025 systematic review and meta-analysis, oral enclomiphene reliably raises testosterone, LH, and FSH in men with secondary hypogonadism — and, unlike topical testosterone, it preserves or increases gonadotropins and sperm counts. The 2025 meta-analysis quantifies it: SERM therapy raised total testosterone by roughly 274 ng/dL versus placebo, with no testosterone difference versus testosterone gel but significantly higher LH and FSH — the biochemical basis for the fertility-preserving claim. A 2024 comparison found enclomiphene had fewer adverse effects and a smaller estradiol rise than racemic clomiphene. That earns a genuine Grade B (the meta-analysis A/B). But the ceiling is real: the strongest signal is short-term biochemistry, not long-term clinical outcomes or fertility hard-endpoints (conception, live birth); standalone enclomiphene is unapproved after an FDA CRL and an EMA refusal; and reviewers have cautioned against over-reading "biochemical improvement" as proven clinical benefit. The grades below keep the solid endocrine RCT evidence separate from the regulatory and long-term-outcome gaps.

Enclomiphene vs its SERM siblings and the alternatives.

The natural comparison set is the SERM family and the testosterone-raising alternatives. Enclomiphene is the purified trans-isomer of clomiphene — so its closest relative is clomiphene citrate itself, the approved (for female ovulation induction) mixed-isomer drug used off-label in men, of which enclomiphene is the more anti-estrogenic, shorter-lived half. Tamoxifen is another SERM with a strong oncology track record and occasional off-label male-endocrine use, while raloxifene sits in the same broad family but targets bone/breast-cancer risk rather than testosterone restoration. The mechanistically different alternative is hCG, an injectable LH-receptor agonist used in specific fertility/hypogonadism indications. The table keeps the regulatory reality visible: enclomiphene is the only row with no approved indication anywhere, and clomiphene's male use — like enclomiphene's — is off-label.

Related compounds.

Because enclomiphene is not a peptide, these are related compounds — SERM siblings and testosterone-axis alternatives — rather than related peptides.

The same compound, three depths.

Source register.

Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. Enclomiphene's pattern resembles tesofensine's: the high-grade sources are genuine human evidence — a 2025 systematic review/meta-analysis (the single A-grade anchor) and multiple randomized phase-II trials (Wiehle, Kaminetsky, Kim, Saffati), all Grade B. Identity, regulatory (FDA CRL / EMA refusal), anti-doping, the clomiphene safety label, and narrative reviews are Grade D. There is no approved-product label, which is exactly why even strong biochemical evidence is capped below approved drugs. The grade distribution makes the page's core point visible: a reproducible, meta-analytically supported endocrine effect — testosterone up, fertility preserved — attached to a compound that two major regulators declined to approve and that remains prohibited in sport.

More Hormone / Reproductive peptides & tools.